A medical diagnostics company, Exagen makes blood tests that help rheumatologists tell apart autoimmune conditions like lupus and rheumatoid arthritis. Its flagship product, AVISE CTD, is processed in a single lab in Vista, California, with results typically ready in about five business days. Founded in 2002, the company grows its line of AVISE-branded tests, and the "CTD" in its flagship test's name stands for connective tissue disease—the family of illnesses it helps doctors sort out.
Exagen director Ana Hooker resigns from board effective April 17, 2026
Hooker served on the Audit Committee and chaired the Nominating and Corporate Governance Committee.
Show detailsHide details
Ana Hooker resigned from Exagen Inc.'s Board of Directors and all committees, effective April 17, 2026.
Her resignation was not due to any disagreement with the company on operations, policies, or practices.
The board size was reduced from eight to seven members effective the same date.
Committee memberships were updated; Paul Kim and Frank Stokes remain financial experts.
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 9.01 Financial Statements and Exhibits
Exagen reports record Q3 2025 revenue of $17.2M, up 38% year-over-year
Q3 2025 revenue was $17.2 million, a 38% increase from $12.5 million in Q3 2024.
Show detailsHide details
Gross margin improved to 58.4% in Q3 2025 from 55.8% in Q3 2024.
Net loss widened to $7.1 million in Q3 2025 from $5.0 million in Q3 2024, partly due to a $2.7 million change in fair value of warrant liability.
Cash and cash equivalents stood at $35.7 million at September 30, 2025, up from $22.0 million at year-end 2024.
Company reiterates 2025 full-year revenue guidance of $65 million to $70 million, with positive adjusted EBITDA expected in Q4 at the high end of the range.
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits